Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: Q-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of Q2043
Per infusion (minimum 50 million cells)
Medicare payment limit per unit (Q4 2026): $55,663.131
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 1 | 2 Date of Service Edit: PolicyDate-of-service edit (policy): units above the value for the same patient and date are considered contrary to statute, regulation, or CMS guidance. | Code Descriptor / CPT Instruction |
| Facility outpatient hospital services | 1 | 2 Date of Service Edit: PolicyDate-of-service edit (policy): units above the value for the same patient and date are considered contrary to statute, regulation, or CMS guidance. | Code Descriptor / CPT Instruction |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$55,663.131per Per infusion (minimum 50 million cells)
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $55,663.131 | Per infusion (minimum 50 million cells) | 20% | −0.5% | — |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $55,932.427 | Per infusion (minimum 50 million cells) | 20% |
Medicare hospital outpatient (OPPS) · Q4 2026
K Paid separately (non-pass-through drug or biological)
$55,663.131 per unit · APC 9273 · copayment $1,736.000 per unit
CMS note: “Copayments capped at inpatient deductible of $1,736.00.”
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 30237-8900-06 | ProvengeDendreon Pharmaceuticals LLC | 250 × 1 | 1 | 1 | $55,663.13 | ASP | Q1 2021 – Q4 2026 | ListedProvenge |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jul 1, 2011 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| −0.6% |
| — |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $56,269.192 | Per infusion (minimum 50 million cells) | 20% | +3.4% | — |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $54,404.108 | Per infusion (minimum 50 million cells) | 20% | −1.6% | — |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $55,272.324 | Per infusion (minimum 50 million cells) | 20% | −1.2% | — |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $55,945.971 | Per infusion (minimum 50 million cells) | 20% | −1.9% | — |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $57,017.103 | Per infusion (minimum 50 million cells) | 20% | +2.7% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $55,536.498 | Per infusion (minimum 50 million cells) | 20% | +0.9% | — |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $55,015.225 | Per infusion (minimum 50 million cells) | 20% | −0.9% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $55,512.784 | Per infusion (minimum 50 million cells) | 20% | +0.1% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $55,453.567 | Per infusion (minimum 50 million cells) | 20% | +3.8% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $53,426.656 | Per infusion (minimum 50 million cells) | 20% | −0.1% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $53,472.873 | Per infusion (minimum 50 million cells) | 20% | +0.8% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $53,062.441 | Per infusion (minimum 50 million cells) | 20% | −1.1% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $53,630.369 | Per infusion (minimum 50 million cells) | 20% | −0.7% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $53,981.464 | Per infusion (minimum 50 million cells) | — | +0.9% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $53,505.534 | Per infusion (minimum 50 million cells) | — | −2.9% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $55,114.745 | Per infusion (minimum 50 million cells) | — | +4.2% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $52,916.501 | Per infusion (minimum 50 million cells) | — | +0.9% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $52,421.579 | Per infusion (minimum 50 million cells) | — | −1.1% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $53,017.576 | Per infusion (minimum 50 million cells) | — | +2.5% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $51,712.975 | Per infusion (minimum 50 million cells) | — | +0.7% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $51,363.252 | Per infusion (minimum 50 million cells) | — | +3.5% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $49,649.408 | Per infusion (minimum 50 million cells) | — | — | — |
|---|